Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M

BIODESIX INC

2025-FY EPS reported -$4.67 revenue$88,499,000

Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.
Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.
FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).
First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.
Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.